| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Xiaofeng Guo, Jinguo Zhai, Qinling Wei, Elizabeth W Twamley, Hua Jin, Maosheng Fang, Maorong Hu, Jingping Zha. Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study. Neuroscience letters. vol 503. issue 2. 2012-01-13. PMID:21888948. |
in a 12-month, open-label, multicenter study, 698 patients with early-stage schizophrenia (duration of illness ≤5 years) were prescribed chlorpromazine, sulpiride, clozapine, risperidone, olanzapine, quetiapine, or aripiprazole monotherapy. |
2012-01-13 |
2023-08-12 |
Not clear |
| Norio Yasui-Furukori, Shoko Tsuchimine, Manabu Saito, Taku Nakagami, Norio Sugawara, Akira Fujii, Sunao Kanek. Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone. Journal of clinical psychopharmacology. vol 31. issue 5. 2011-12-27. PMID:21869689. |
sixty patients with acute exacerbations of schizophrenia received 6 mg/d of risperidone for 4 weeks. |
2011-12-27 |
2023-08-12 |
Not clear |
| Neil M Richtand, Rebecca Ahlbrand, Paul Horn, Kevin Stanford, Stefanie L Bronson, Robert K McNamar. Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation. Journal of psychiatric research. vol 45. issue 9. 2011-12-23. PMID:21440257. |
we aimed to extend those findings evaluating risperidone and paliperidone following prenatal immune activation, a developmental model of a schizophrenia risk factor. |
2011-12-23 |
2023-08-12 |
Not clear |
| Vicente Molina, Carmen Martín, Alejandro Ballesteros, Alba G Seco de Herrera, Juan Antonio Hernández-Tamame. Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics. European archives of psychiatry and clinical neuroscience. vol 261. issue 6. 2011-12-21. PMID:21191610. |
to this end, in this study, magnetic resonance imaging (mri) and voxel-based morphometry (vbm) were used to assess the relationship between the brain volumes of gray (gm) and white (wm) matters and the clinical response to risperidone or olanzapine in 30 schizophrenia patients. |
2011-12-21 |
2023-08-12 |
Not clear |
| Vicente Molina, Carmen Martín, Alejandro Ballesteros, Alba G Seco de Herrera, Juan Antonio Hernández-Tamame. Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics. European archives of psychiatry and clinical neuroscience. vol 261. issue 6. 2011-12-21. PMID:21191610. |
this study reveals a pattern of structural alterations in schizophrenia associated with the response to risperidone or olanzapine. |
2011-12-21 |
2023-08-12 |
Not clear |
| Kun Kim, Eline Aa. Cost-effectiveness analysis of olanzapine and risperidone in Norway. The journal of mental health policy and economics. vol 14. issue 3. 2011-12-20. PMID:22116170. |
antipsychotic medications are the mainstay for schizophrenia treatment, and olanzapine and risperidone are popular choices among atypical antipsychotics in norway. |
2011-12-20 |
2023-08-12 |
Not clear |
| Shi-Fu Xiao, Hai-Bo Xue, Xia Li, Chao Chen, Guan-Jun Li, Cheng-Mei Yuan, Ming-Yuan Zhan. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. Neuroscience bulletin. vol 27. issue 4. 2011-12-06. PMID:21788997. |
a double-blind, placebo-controlled study of traditional chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. |
2011-12-06 |
2023-08-12 |
human |
| Shi-Fu Xiao, Hai-Bo Xue, Xia Li, Chao Chen, Guan-Jun Li, Cheng-Mei Yuan, Ming-Yuan Zhan. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. Neuroscience bulletin. vol 27. issue 4. 2011-12-06. PMID:21788997. |
objective to identify whether sarsasapogenin, a sapogenin from the chinese medicinal herb anemarrhena asphodeloides bunge, would augment the efficacy of risperidone and significantly improve cognitive functions in patients with negative symptoms dominated schizophrenia. |
2011-12-06 |
2023-08-12 |
human |
| Shi-Fu Xiao, Hai-Bo Xue, Xia Li, Chao Chen, Guan-Jun Li, Cheng-Mei Yuan, Ming-Yuan Zhan. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. Neuroscience bulletin. vol 27. issue 4. 2011-12-06. PMID:21788997. |
conclusion sarsasapogenin did not augment the efficacy of risperidone in treating negative symptoms dominated schizophrenia. |
2011-12-06 |
2023-08-12 |
human |
| Shi-Fu Xiao, Hai-Bo Xue, Xia Li, Chao Chen, Guan-Jun Li, Cheng-Mei Yuan, Ming-Yuan Zhan. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. Neuroscience bulletin. vol 27. issue 4. 2011-12-06. PMID:21788997. |
sarsasapogenin at a dosage of 200 mg per day added to a flexible dosage of risperidone at 2-4 mg per day is safe and well tolerated by patients with negative symptoms dominated schizophrenia. |
2011-12-06 |
2023-08-12 |
human |
| Alessandro Zuddas, Roberta Zanni, Tatiana Usal. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 21. issue 8. 2011-11-28. PMID:21550212. |
sgas efficacy on mania, extreme mood variability, irritability, aggression and disruptive behavior appears to be greater than for psychotic symptoms in schizophrenia: average nnt was 2-5, whereas for schizophrenia it varies between 3 for risperidone and 10 for olanzapine, quetiapine, and aripiprazole. |
2011-11-28 |
2023-08-12 |
Not clear |
| Paul G Barnett, Jennifer Y Scott, Robert A Rosenhec. How do clinical trial participants compare to other patients with schizophrenia? Schizophrenia research. vol 130. issue 1-3. 2011-11-23. PMID:21514794. |
patients with schizophrenia enrolled in a trial of long-acting injectable risperidone at multiple sites of the veterans health administration (vha). |
2011-11-23 |
2023-08-12 |
human |
| Vishal Madaan, Durga P Bestha, Venkata Kolli, Saurabh Jauhari, Roger C Burke. Clinical utility of the risperidone formulations in the management of schizophrenia. Neuropsychiatric disease and treatment. vol 7. 2011-11-23. PMID:22090797. |
clinical utility of the risperidone formulations in the management of schizophrenia. |
2011-11-23 |
2023-08-12 |
human |
| Vishal Madaan, Durga P Bestha, Venkata Kolli, Saurabh Jauhari, Roger C Burke. Clinical utility of the risperidone formulations in the management of schizophrenia. Neuropsychiatric disease and treatment. vol 7. 2011-11-23. PMID:22090797. |
risperidone is currently one of the most widely prescribed antipsychotic medications, used for both acute and long-term maintenance in schizophrenia. |
2011-11-23 |
2023-08-12 |
human |
| Ichiro Kusumi, Minoru Honda, Koichi Ito, Keiichi Uemura, Yukie Kumazawa, Tomohito Ishikane, Yasushi Niide, Tsukasa Koyam. Risperidone oral solution versus standard tablets for the acute treatment of patients with schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 2. 2011-11-22. PMID:21168464. |
risperidone oral solution versus standard tablets for the acute treatment of patients with schizophrenia. |
2011-11-22 |
2023-08-12 |
Not clear |
| Chikako Ohta, Norio Yasui-Furukori, Hanako Furukori, Shoko Tsuchimine, Manabu Saito, Taku Nakagami, Kaori Yoshizawa, Sunao Kanek. The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 2. 2011-11-22. PMID:21216266. |
the effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients. |
2011-11-22 |
2023-08-12 |
human |
| Chikako Ohta, Norio Yasui-Furukori, Hanako Furukori, Shoko Tsuchimine, Manabu Saito, Taku Nakagami, Kaori Yoshizawa, Sunao Kanek. The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 2. 2011-11-22. PMID:21216266. |
subjects included 154 schizophrenia patients (61 males, 93 females) who had received 3 mg of risperidone twice daily for at least 4 weeks. |
2011-11-22 |
2023-08-12 |
human |
| Chien-Chih Chen, Tiao-Lai Huan. Effects of antipsychotics on the serum BDNF levels in schizophrenia. Psychiatry research. vol 189. issue 3. 2011-11-15. PMID:21320726. |
specifically, this study measured serum bdnf levels in 53 patients with paranoid schizophrenia during a relapse and again 4 weeks following the administration of antipsychotic treatment (with risperidone in 32 cases, and clozapine in 21 cases). |
2011-11-15 |
2023-08-12 |
human |
| Maximilian Gahr, Markus A Kölle, Carlos Schönfeldt-Lecuona, Peter Lepping, Roland W Freudenman. Paliperidone extended-release: does it have a place in antipsychotic therapy? Drug design, development and therapy. vol 5. 2011-11-15. PMID:21448450. |
paliperidone (9-hydroxy-risperidone), the active metabolite of risperidone, was approved for treating schizophrenia worldwide in 2006 as paliperidone extended-release (per), and became the first second-generation antipsychotic specifically licensed for treating schizoaffective disorder in 2009. |
2011-11-15 |
2023-08-12 |
Not clear |
| Fabrice Bon, Eric Louis Constant, Peter Goethals, Daniel Ne. Absence of cardiac side effects during treatment of schizophrenia with risperidone in a patient with wolff-Parkinson-white syndrome. Primary care companion to the Journal of clinical psychiatry. vol 9. issue 3. 2011-11-10. PMID:17632661. |
absence of cardiac side effects during treatment of schizophrenia with risperidone in a patient with wolff-parkinson-white syndrome. |
2011-11-10 |
2023-08-12 |
Not clear |